Advanced Liver Cancer Market Report 2026

Advanced Liver Cancer Market Overview

• Advanced Liver Cancer market size has reached to $2.16 billion in 2025 • Expected to grow to $4.27 billion in 2030 at a compound annual growth rate (CAGR) of 14.5% • Growth Driver: Rising Prevalence Of Long-Term Hepatitis Infections Driving Growth In The Market • Market Trend: Integrated Multidisciplinary Clinics Enhance Patient-Centric Care In Advanced Liver Cancer • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Advanced Liver Cancer Market?

Advanced liver cancer, also known as hepatocellular carcinoma (HCC) in its later stages, refers to liver cancer that has spread beyond the liver or grown large enough to affect liver function significantly. In this stage, the cancer may have invaded nearby blood vessels, lymph nodes, or distant organs, making treatment more challenging. Symptoms often include jaundice, abdominal pain, weight loss, and fatigue. The main test types for advanced liver cancer are imaging tests, biopsies, genomic tests, and others. Imaging tests are crucial for diagnosing, staging, and treating hepatocellular carcinoma (HCC) by providing detailed views of the liver and surrounding organs. It includes various technologies such as fluorescent in situ hybridization, next-generation sequencing, fluoroimmunoassay, comparative genomic hybridization, immunohistochemical, and others, and is distributed through various distribution channels, including direct tenders, retail sales, and others. It is applicable for several applications, such as screening, diagnostic and predictive, prognostic, and research, and is used by various end users, including hospitals, cancer research centers, academic institutes, diagnostic centers, ambulatory surgical centers, and others.

What Is The Advanced Liver Cancer Market Growth Forecast?

The advanced liver cancer market size is expected to see rapid growth in the next few years. It will grow to $4.27 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to advancement in genomic testing technologies, increasing implementation of personalized medicine, growth of screening and predictive diagnostics, rising collaborations between hospitals and research centers, expansion of ambulatory surgical centers. Major trends in the forecast period include rising adoption of ngs and genomic testing for hcc, increasing use of imaging and biopsy techniques, growth in prognostic and predictive diagnostics, expansion of liver cancer research initiatives, focus on early detection and personalized treatment approaches.

Global Advanced Liver Cancer Market Segmentation

1) By Test Type: Imaging Test, Biopsy, Genomic Test, Other Test Types 2) By Technology: Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, Other Technologies 3) By Distribution Channel: Direct Tenders, Retail Sales, Other Distribution Channel 4) By Application: Diagnostic And Predictive, Prognostic, Research 5) By End-User: Hospitals, Cancer Research Centers, Academic Institutes, Diagnostic Centers, Other End-Users Subsegments: 1) By Imaging Test: Ultrasound, CT (Computed Tomography) Scan, MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography) Scan 2) By Biopsy: Needle Biopsy, Laparoscopic Biopsy, Surgical Biopsy 3) By Genomic Test: Next-Generation Sequencing (NGS), PCR (Polymerase Chain Reaction) Testing, Genetic Mutation Profiling 4) By Other Test Types: Serum Biomarker Testing, Liver Function Tests, Alpha-Fetoprotein (AFP) Test, Elastography Tests

What Is The Driver Of The Advanced Liver Cancer Market?

The rising prevalence of long-term hepatitis infections is expected to propel the growth of the advanced liver cancer market going forward. Long-term hepatitis infections are long-lasting viral infections that endure for over six months and can result in liver damage, cirrhosis, or liver cancer. The increase in long-term hepatitis infections can be attributed to factors such as inadequate screening and vaccination and delayed access to treatment. Chronic infections with hepatitis B (HBV) or hepatitis C (HCV) are among the leading causes of liver cirrhosis and hepatocellular carcinoma (HCC), the most common form of liver cancer. Long-term viral infections can lead to liver inflammation, liver damage, and eventually cancer over time. As these infections remain prevalent, more individuals are at risk of developing advanced liver cancer. For instance, in April 2025, according to ASHM, an Australia-based peak organisation of health professionals, in 2023, approximately 219,800 individuals in Australia were living with chronic hepatitis B (CHB), accounting for around 0.82% of the country’s population. Therefore, the rising prevalence of long-term hepatitis infections is driving the growth of the advanced liver cancer industry.

Key Players In The Global Advanced Liver Cancer Market

Major companies operating in the advanced liver cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Agilent Technologies Inc., Eisai Co. Ltd., Jiangsu Hengrui Pharmaceutical Co. Ltd, Exelixis Inc., Sirtex Medical Limited, Eureka Therapeutics, Abbisko Therapeutics Co. Ltd., Binhui Biopharmaceutical Co. Ltd., Tempest Therapeutics Inc., Auransa Inc., Mina Alpha Limited, Jennerex Inc.

Global Advanced Liver Cancer Market Trends and Insights

Major companies operating in the advanced liver cancer market are focusing on developing integrated multidisciplinary clinics to enhance patient-centric care, improve treatment coordination, and streamline clinical decision-making. A multidisciplinary clinic brings together specialists from oncology, hepatobiliary surgery, interventional radiology, genetics, pathology, anesthesia, and palliative care to collaboratively plan therapy for complex liver cancer cases, ensuring tailored interventions and reduced delays. For instance, in July 2025, Apollo Proton Cancer Centre, an India-based cancer-treatment provider, opened its Advanced Liver Cancers Clinic, which integrates care for primary liver cancers and liver metastases in a single center. The clinic unites medical oncologists, hepatobiliary surgeons, interventional radiologists, geneticists, pathologists, and palliative care experts to establish standardized treatment pathways. It also plans to conduct prospective research, explore novel therapies, and prioritize the patient’s entire care journey, addressing the growing need for specialized liver cancer programs in India amid a rising burden of hepatocellular carcinoma driven by hepatitis, fatty liver disease, and late diagnosis.

What Are Latest Mergers And Acquisitions In The Advanced Liver Cancer Market?

In March 2023, the University of Southern California (USC), a US-based private research university, collaborated with Auransa Inc. to advance clinical trials for a new targeted liver cancer treatment. This collaboration combines their expertise to improve treatment efficacy for liver cancer and other solid tumors. Auransa Inc. is a US-based pharmaceutical company treating advanced liver cancers.

Regional Outlook

North America was the largest region in the advanced liver cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Advanced Liver Cancer Market?

The advanced liver cancer market consists of revenues earned by entities that provide services such as diagnostic services, surgical services, patient support and management. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced liver cancer market also includes sales of biopsy tools, computed tomography (CT) scans, liver function tests kit, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Advanced Liver Cancer Market Report 2026?

The advanced liver cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the advanced liver cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.